title: Prognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib.
abstract: OBJECTIVE
  This study aimed to investigate whether the pathological features of primary lesions show additional prognostic value in patients with metastatic renal cell carcinoma who are treated with sorafenib.
  
  
  METHODS
  A consecutive cohort of 284 patients was included from Fudan University Shanghai Cancer Center between 2007 and 2013. The association between survival and pathological features of primary tumors was assessed using the Cox proportional hazards model. The incremental value of prognostication was evaluated.
  
  
  RESULTS
  We found that the pathological features of primary lesions provided added prognostic value over the Memorial Sloan-Kettering Cancer Center model in patients with metastatic renal cell carcinoma who were treated with sorafenib.
  
  
  CONCLUSIONS
  Addition of a pathological score in the clinical setting could better identify patients at risk of poor survival.
authors.affiliation: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.
authors.forename: Weijie
authors.initials: W
authors.lastname: Gu
authors.affiliation: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.
authors.forename: Beihe
authors.initials: B
authors.lastname: Wang
authors.affiliation: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.|Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.
authors.forename: Hualei
authors.initials: H
authors.lastname: Gan
authors.affiliation: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.
authors.forename: Yao
authors.initials: Y
authors.lastname: Zhu
authors.affiliation: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.
authors.forename: Hongkai
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.
authors.forename: Guohai
authors.initials: G
authors.lastname: Shi
authors.affiliation: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.|Department of Radiology, Fudan University, Shanghai Cancer Center, Shanghai 200032, PR China.
authors.forename: Liangpin
authors.initials: L
authors.lastname: Zhou
authors.affiliation: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.
authors.forename: Hailiang
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.
authors.forename: Dingwei
authors.initials: D
authors.lastname: Ye
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D011379:Prognosis; D016016:Proportional Hazards Models; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib
keywords: International Society of Urological Pathology; pathological features; prognosis; renal cell carcinoma; sorafenib